Konrad H. Stopsack
Secondary Faculty

Konrad H. Stopsack

Assistant Professor in the Department of Epidemiology

Epidemiology

stopsack@hsph.harvard.edu

Other Positions

Assistant Professor of Medicine

Medicine-Massachusetts General Hospital

Harvard Medical School


Overview

I am a molecular and clinical epidemiologist with a focus on cancer epidemiology and a background as a board-certified internal medicine physician. My main research interest is how potentially modifiable exposures cause solid tumors through genomic heterogeneity and influence cancer progression. I am passionate about combining well-defined observational studies and state-of-the-art genomics in order to guide cancer prevention and treatment. My methodologic and teaching interests include application and further development of epidemiologic methods for high-dimensional biomarker studies and clinical studies.

MD, 2013, Medicine
University of Freiburg, Freiburg, Germany

MPH, 2014, Biostatistics and Epidemiology
Harvard School of Public Health, Boston, MA

Residency, Board certification, 2017, Internal Medicine
Mayo Clinic, Rochester, MN

Postdoctoral training, 2021, Cancer Epidemiology
Memorial Sloan Kettering Cancer Center, New York, NY


Bibliography

Characterising the contribution of rare protein-coding germline variants to prostate cancer risk and severity in 37,184 cases.

Mitchell J, Camacho N, Shea P, Stopsack KH, Joseph V, Burren O, Dhindsa R, Nag A, Berchuck JE, O'Neill A, Abbasi A, Zoghbi AW, Alegre-Díaz J, Kuri-Morales P, Berumen J, Tapia-Conyer R, Emberson J, Torres JM, Collins R, Wang Q, Goldstein D, Matakidou A, Haefliger C, Anderson-Dring L, March R, Jobanputra V, Dougherty B, Carss K, Petrovski S, Kantoff PW, Offit K, Mucci LA, Pomerantz M, Fabre MA.

medRxiv. 2024 May 10. PMID: 38766261

Marital Status, Living Arrangement, and Survival among Individuals with Advanced Prostate Cancer in the International Registry for Men with Advanced Prostate Cancer.

Chen N, McGrath CB, Ericsson CI, Vaselkiv JB, Rencsok EM, Stopsack KH, Guard HE, Autio KA, Rathkopf DE, Enting D, Bitting RL, Mateo J, Githiaka CW, Chi KN, Cheng HH, Davis ID, Anderson SG, Badal SAM, Bjartell A, Russnes KM, Heath EI, Pomerantz MM, Henegan JC, Hyslop T, Esteban E, Omlin A, McDermott R, Fay AP, Popoola AA, Ragin C, Nowak J, Gerke T, Kantoff PW, George DJ, Penney KL, Mucci LA.

Cancer Epidemiol Biomarkers Prev. 2024 03 01. 33(3):419-425. PMID: 38189661

Germline Sequencing Analysis to Inform Clinical Gene Panel Testing for Aggressive Prostate Cancer.

Darst BF, Saunders E, Dadaev T, Sheng X, Wan P, Pooler L, Xia LY, Chanock S, Berndt SI, Wang Y, Patel AV, Albanes D, Weinstein SJ, Gnanapragasam V, Huff C, Couch FJ, Wolk A, Giles GG, Nguyen-Dumont T, Milne RL, Pomerantz MM, Schmidt JA, Travis RC, Key TJ, Stopsack KH, Mucci LA, Catalona WJ, Marosy B, Hetrick KN, Doheny KF, MacInnis RJ, Southey MC, Eeles RA, Wiklund F, Conti DV, Kote-Jarai Z, Haiman CA.

JAMA Oncol. 2023 Nov 01. 9(11):1514-1524. PMID: 37733366